We are analyzing https://link.springer.com/article/10.1007/s12603-013-0003-1.

Title:
Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement | The journal of nutrition, health & aging
Description:
Multidisciplinary basic research led to an evolving knowledge of the molecular pathogenesis of Alzheimer’s disease (AD). These advances have been translated into defined therapeutic concepts and distinct classes of compounds with putative disease-modifying effects that are now being tested in clinical trials. There is a growing consensus that disease-modifying treatments may be most effective when commenced early in the course and progression of AD pathophysiology, before amyloid deposition and neurodegeneration become too widespread. Biological indicators of pathophysiological mechanisms are required to chart and identify AD in the prodromal phase or, preferably, in asymptomatic individuals. Biomarkers are becoming even more important, owing to the challenges in demonstrating efficacy of candidate-drugs that hit pathophysiological targets using clinical and cognitive outcomes in early AD trials with limited duration. Currently, there is emerging consensus that advances in therapeutic strategies for AD that delay predefined milestones or slow the cognitive and disease progression would considerably decrease the expanding global burden of the disease. To effectively test preventive compounds for AD and bring therapy to affected individuals as early as possible there is an urgent need for a concerted collaboration among worldwide academic institutions, industry, and regulatory bodies with the aim of establishing networks for the identification and qualification of multi-modal biological disease markers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

article, alzheimers, google, scholar, pubmed, disease, cas, blennow, biomarkers, hampel, zetterberg, neurol, alzheimer, fluid, cerebrospinal, amyloid, cognitive, csf, research, minthon, wallin, markers, aisen, patients, trials, early, dement, tau, weiner, diagnosis, holtzman, impairment, psychiatry, dis, morris, drug, plasma, scheltens, mild, med, res, aging, mechanisms, clinical, biological, development, neurosci, shaw, jack, petersen,

Topics {✒️}

high-molecular-weight {beta}-amyloid oligomers month download article/chapter csf aβ42/aβ40 ratio blood-based microcirculation markers amyloid-beta homeostasis markers gamma-secretase inhibitor n2-[ phase ii/iii trials amyloid beta-related mechanisms drugs targeting beta-amyloid β-amyloid peptide signatures amyloid cascade hypothesis blood-brain barrier disturbance target engagement published jack cr jr post-lumbar puncture headache ]azepin-7-yl]-l-alaninamide copper-zinc chelator markedly transforming growth factor-betal serum protein-based algorithm gamma-secretase inhibitors bms-289948 putative disease-modifying effects bt2-201-euro study group population-based autopsy study blood-based algorithm target engagement upcoming prevention trials early ad trials gamma-secretase inhibitor theragnostic markers hit pathophysiological targets gispen-de wied cc beta-amyloid concentrations prodromal phase modifying therapy pathophysiological mechanisms age-based hypothesis full article pdf proteome-based plasma biomarkers phosphorylated tau protein prevention trials asymptomatic individuals privacy choices/manage cookies disease therapeutic trials disease-modifying treatments clinical trials molecular mechanism beta-amyloid jack cr amyloid hypothesis task force report

Questions {❓}

Workman P (2003) How much gets there and what does it do?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement
         description:Multidisciplinary basic research led to an evolving knowledge of the molecular pathogenesis of Alzheimer’s disease (AD). These advances have been translated into defined therapeutic concepts and distinct classes of compounds with putative disease-modifying effects that are now being tested in clinical trials. There is a growing consensus that disease-modifying treatments may be most effective when commenced early in the course and progression of AD pathophysiology, before amyloid deposition and neurodegeneration become too widespread. Biological indicators of pathophysiological mechanisms are required to chart and identify AD in the prodromal phase or, preferably, in asymptomatic individuals. Biomarkers are becoming even more important, owing to the challenges in demonstrating efficacy of candidate-drugs that hit pathophysiological targets using clinical and cognitive outcomes in early AD trials with limited duration. Currently, there is emerging consensus that advances in therapeutic strategies for AD that delay predefined milestones or slow the cognitive and disease progression would considerably decrease the expanding global burden of the disease. To effectively test preventive compounds for AD and bring therapy to affected individuals as early as possible there is an urgent need for a concerted collaboration among worldwide academic institutions, industry, and regulatory bodies with the aim of establishing networks for the identification and qualification of multi-modal biological disease markers.
         datePublished:2013-01-09T00:00:00Z
         dateModified:2013-01-09T00:00:00Z
         pageStart:54
         pageEnd:63
         sameAs:https://doi.org/10.1007/s12603-013-0003-1
         keywords:
            Alzheimer’s disease
            AD
            MCI
            prodromal
            asymptomatic
            amyloid cascade hypothesis
            amyloid-beta
            tau
            biomarkers
            theragnostic biomarkers
            target engagement
            mechanism of action
            pathophysiological mechanisms
            neurobiochemical markers
            CSF
            blood
            early detection
            disease-modifying compounds
            therapy
            clinical trials
            prevention trials
            Geriatrics/Gerontology
            Nutrition
            Aging
            Neurosciences
            Primary Care Medicine
            Quality of Life Research
         image:
         isPartOf:
            name:The journal of nutrition, health & aging
            issn:
               1760-4788
               1279-7707
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Harald Hampel
               affiliation:
                     name:Goethe-University
                     address:
                        name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
                        type:PostalAddress
                     type:Organization
                     name:Goethe-University of Frankfurt
                     address:
                        name:Department of Psychiatry, Goethe-University of Frankfurt, Frankfurt am Main, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:S. Lista
               affiliation:
                     name:Goethe-University
                     address:
                        name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement
      description:Multidisciplinary basic research led to an evolving knowledge of the molecular pathogenesis of Alzheimer’s disease (AD). These advances have been translated into defined therapeutic concepts and distinct classes of compounds with putative disease-modifying effects that are now being tested in clinical trials. There is a growing consensus that disease-modifying treatments may be most effective when commenced early in the course and progression of AD pathophysiology, before amyloid deposition and neurodegeneration become too widespread. Biological indicators of pathophysiological mechanisms are required to chart and identify AD in the prodromal phase or, preferably, in asymptomatic individuals. Biomarkers are becoming even more important, owing to the challenges in demonstrating efficacy of candidate-drugs that hit pathophysiological targets using clinical and cognitive outcomes in early AD trials with limited duration. Currently, there is emerging consensus that advances in therapeutic strategies for AD that delay predefined milestones or slow the cognitive and disease progression would considerably decrease the expanding global burden of the disease. To effectively test preventive compounds for AD and bring therapy to affected individuals as early as possible there is an urgent need for a concerted collaboration among worldwide academic institutions, industry, and regulatory bodies with the aim of establishing networks for the identification and qualification of multi-modal biological disease markers.
      datePublished:2013-01-09T00:00:00Z
      dateModified:2013-01-09T00:00:00Z
      pageStart:54
      pageEnd:63
      sameAs:https://doi.org/10.1007/s12603-013-0003-1
      keywords:
         Alzheimer’s disease
         AD
         MCI
         prodromal
         asymptomatic
         amyloid cascade hypothesis
         amyloid-beta
         tau
         biomarkers
         theragnostic biomarkers
         target engagement
         mechanism of action
         pathophysiological mechanisms
         neurobiochemical markers
         CSF
         blood
         early detection
         disease-modifying compounds
         therapy
         clinical trials
         prevention trials
         Geriatrics/Gerontology
         Nutrition
         Aging
         Neurosciences
         Primary Care Medicine
         Quality of Life Research
      image:
      isPartOf:
         name:The journal of nutrition, health & aging
         issn:
            1760-4788
            1279-7707
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Harald Hampel
            affiliation:
                  name:Goethe-University
                  address:
                     name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
                     type:PostalAddress
                  type:Organization
                  name:Goethe-University of Frankfurt
                  address:
                     name:Department of Psychiatry, Goethe-University of Frankfurt, Frankfurt am Main, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:S. Lista
            affiliation:
                  name:Goethe-University
                  address:
                     name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:The journal of nutrition, health & aging
      issn:
         1760-4788
         1279-7707
      volumeNumber:17
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Goethe-University
      address:
         name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
         type:PostalAddress
      name:Goethe-University of Frankfurt
      address:
         name:Department of Psychiatry, Goethe-University of Frankfurt, Frankfurt am Main, Germany
         type:PostalAddress
      name:Goethe-University
      address:
         name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Harald Hampel
      affiliation:
            name:Goethe-University
            address:
               name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
               type:PostalAddress
            type:Organization
            name:Goethe-University of Frankfurt
            address:
               name:Department of Psychiatry, Goethe-University of Frankfurt, Frankfurt am Main, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:S. Lista
      affiliation:
            name:Goethe-University
            address:
               name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
      name:Department of Psychiatry, Goethe-University of Frankfurt, Frankfurt am Main, Germany
      name:Department of Psychiatry, Goethe-University, Frankfurt, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(265)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.31s.

LINK . SPRINGER . COM {}